[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507348":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":23,"responsibleParty":45,"collaborators":7,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":7,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":7,"enrollmentInfo":56,"targetDuration":7,"studyType":59,"phases":7,"briefSummary":60,"conditions":61,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"University of California, Davis","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Quantitative Neuromuscular Function Monitoring","Quantitative electromyographic (EMG) monitoring",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Ana P Arias, BS","CONTACT","916-703-5456","apaarias@ucdavis.edu",{"name":20,"role":16,"phone":21,"phoneExt":7,"email":22},"Julio J Arana Pineda, BA","916-734-4074","jjaranapineda@ucdavis.edu",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"UC Davis Medical Center","RECRUITING","Sacramento","California","95817","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-121.4944,38.58157,{"lat":36,"lon":35},[39,41],{"name":40,"role":16,"phone":17,"phoneExt":7,"email":18},"Ana Arias",{"name":42,"role":16,"phone":43,"phoneExt":7,"email":44},"Neal Fleming, MD, PhD","916 734-5046","nwfleming@ucdavis.edu",{"type":46,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100507348","quantitative-neuromuscular-monitoring-and-gastric-bypass-surgery-100507348",false,"NCT05886218","Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery","A Before\u002FAfter Study of the Impact of Quantitative Neuromuscular Monitoring and Sugammadex Reversal Following Gastric Bypass Surgery","Inclusion Criteria:\n\n* age greater than 18 years\n* scheduled for an elective laparoscopic gastric bypass procedure\n\nExclusion Criteria:\n\n* age less than 18 years\n* pregnancy\n* prisoners\n* significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication\n* patients who require supplemental oxygen pre-operatively to maintain a hemoglobin saturation (SpO2\\>98%)","ALL","18 Years",{"count":57,"type":58},215,"ESTIMATED","OBSERVATIONAL","This is a single site, prospective, non-blinded, non-randomized, before\u002Fafter study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.",[62],"Sugammadex","2025-05-13",{"date":65,"type":66},"2025-05-15","ACTUAL",{"date":68,"type":66},"2023-02-08",{"date":70,"type":58},"2025-07",{"name":5,"class":6},1]